Table 1.

Characteristics and p-value of patients that have PSA after nadir

	Total	CRPC	p-value
Number of patients	261	96	-
Mean follow-up ± s.d.	38.7 ± 3.5	15.8 ± 2.4	-
Mean age ± s.d.	74 ± 0.9	75.2 ± 1.7	0.011
Mean time to nadir ± s.d.	10.3 ± 1.3	8.9 ± 1.9	0.001
Mean pretreatment PSA ± s.d.	119.4 ± 39.4	151.5 ± 80.3	0.054
Mean PSA nadir ± s.d.	12.8 ± 11.7	6.6 ± 4.2	0.142
Bone metastasis
Yes	41	15	0.490
No	220	79
Gleason score			0.117
≤ 6	59 (22.6 %)	20 (21.2 %)
7	72 (27.5 %)	21 (22.3 %)
≥ 8	130 (49.8 %)	53 (56.3 %)
ADT type
Leuprin only	154	44	0.012
Zoladex only	36	10
Leuprin → Zoladex	9	6
Zoladex → Leuprin	49	27
Anti-androgen only	13	7